Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease

References

• European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999;14(Suppl 5):1–50
   Google Scholar
• IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37(Suppl 1):S182–238
   PubMedGoogle Scholar
• Nissenson AR, Collins AJ, Hurley J, et al. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns. J Am Soc Nephrol 2001;12:1713–20
   PubMed Web of Science ®Google Scholar
• Obrador GT, Ruthazer R, Arora P, et al. Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 1999;10:1793–800
   PubMed Web of Science ®Google Scholar
• Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999;10:1281–6
   PubMed Web of Science ®Google Scholar
• Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol 2001;12:1501–7
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol 2002;58(Suppl 1):S37–45
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141–6
   PubMed Web of Science ®Google Scholar
• Pinevich AJ, Petersen J. Erythropoietin therapy in patients with chronic renal failure. West J Med 1992;157:154–7
   PubMedGoogle Scholar
• Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77:176–85
   PubMed Web of Science ®Google Scholar
• Jungers P, Hannedouche T, Itakura Y, et al. Progression rate to end-stage renal failure in non-diabetic kidney diseases: a multivariate analysis of determinant factors. Nephrol Dial Transplant 1995;10:1353–60
   PubMed Web of Science ®Google Scholar
• Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91: 1616–34
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;392\(Suppl 1):S1–266
   Google Scholar
• Mitch WE, Walser M, Buffington GA, Lemann Jr J. A simple method of estimating progression of chronic renal failure. Lancet 1976;2:1326–8
   Google Scholar
• Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 2003;14(Suppl 2):S173–7
   Google Scholar
• Jungers P, Choukroun G, Oualim Z, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001;16:307–12
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–62
   PubMed Web of Science ®Google Scholar
• Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135:73–87
   PubMed Web of Science ®Google Scholar
• Perico N, Remuzzi G. Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Curr Opin Nephrol Hypertens 1998;7:571–8
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345: 851–60
   PubMed Web of Science ®Google Scholar
• Lewis J, Greene T, Appel L, et al. Effects of interventions on outcomes based on serum creatinine in the African American Study of Kidney Disease (AASK). J Am Soc Nephrol 2002;13:423A [Program and Abstracts Issue]
   Google Scholar